Zai Lab to present Phase 1/1b healthy — volunteer data for atopic disease antibody ZL — 1503 at ACAAI 2026

Zai Lab flagged first clinical data for ZL-1503, a bispecific antibody for atopic diseases, from its Phase 1/1b healthy-volunteer trial. Results have not been presented yet; the initial readout is scheduled for the ACAAI 2026 meeting on Nov. 13. The update will cover how the drug behaved in the body, early biomarker effects, and initial safety and immunogenicity observations. Zai Lab positioned the program as a potentially longer-acting approach aimed at reducing itch and inflammation in IL-13- and IL-31-driven conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via (Ref. ID: 202610140700BIZWIRE_USPR_____20261014_BW931547) on October 14, 2026, and is solely responsible for the information contained therein. (C)